This company has been acquired
INBX Stock Overview
A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Inhibrx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.11 |
| 52 Week High | US$39.79 |
| 52 Week Low | US$14.31 |
| Beta | 2.88 |
| 1 Month Change | -0.55% |
| 3 Month Change | -6.42% |
| 1 Year Change | 38.66% |
| 3 Year Change | 55.97% |
| 5 Year Change | n/a |
| Change since IPO | 65.34% |
Recent News & Updates
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
Nov 05Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Jun 07Recent updates
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
Nov 05Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Jun 07Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?
May 13
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23Shareholder Returns
| INBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.09% | -8.7% | 0.3% |
| 1Y | 38.7% | -15.3% | 8.0% |
Return vs Industry: INBX exceeded the US Biotechs industry which returned 4.6% over the past year.
Return vs Market: INBX exceeded the US Market which returned 25.2% over the past year.
Price Volatility
| INBX volatility | |
|---|---|
| INBX Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: INBX has not had significant price volatility in the past 3 months.
Volatility Over Time: INBX's weekly volatility has decreased from 8% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 169 | Mark Lappe | inhibrx.com |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
| INBX fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | -US$271.15m |
| Revenue (TTM) | US$1.78m |
1,002x
P/S Ratio-6.6x
P/E RatioIs INBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX income statement (TTM) | |
|---|---|
| Revenue | US$1.78m |
| Cost of Revenue | US$218.11m |
| Gross Profit | -US$216.32m |
| Other Expenses | US$54.83m |
| Earnings | -US$271.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.17 |
| Gross Margin | -12,132.47% |
| Net Profit Margin | -15,207.80% |
| Debt/Equity Ratio | 1,799.9% |
How did INBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/31 09:35 |
| End of Day Share Price | 2024/05/29 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inhibrx, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reni Benjamin | Citizens JMP Securities, LLC |
| Martin Auster | Credit Suisse |
| Joshua Schimmer | Evercore ISI |